Observation on clinical effect of Huoxue-Jiangtang decoction formula granules in treating prediabetes: a randomized prospective placebo-controlled double-blind trial protocol

BMC Complement Med Ther. 2022 Oct 19;22(1):274. doi: 10.1186/s12906-022-03755-2.

Abstract

Background: Prediabetes is a hypermetabolic syndrome with blood sugar levels falling between the normal and diabetes. People with prediabetes have a significantly increased chances of developing diabetes, cardiovascular and cerebrovascular diseases, tumors, dementia, and other diseases in the future when compared to the healthy population. However, prediabetes is mainly treated based on lifestyle intervention, currently without targeted drug treatment plan. Traditional Chinese medicine (TCM), which has a longstanding experience, has been shown in clinical studies to be effective for the treatment of diabetes and its related complications. Furthermore, different dosage forms such as decoction and granule have developed gradually in clinical application. Preliminary studies have found that Huoxue-Jangtang Decoction (HJD), with good hypoglycemic and lipid-regulating effects, is potentially one of the complementary and alternative treatments for prediabetes. Therefore, this project intends to perform a prospective clinical study to observe the clinical effectiveness of HJD on prediabetes and the consistency of the efficacy of formula granules and the elixation.

Methods: This is a prospective, randomized, double-blind, and placebo-controlled clinical trial. A total of 183 participants are randomly assigned to HJD Formula Granules plus lifestyle intervention, HJD Elixation plus lifestyle intervention, and placebo plus lifestyle intervention. All subjects undergo 1 day of screening before participating in the study, followed by 84 days of drug intervention and observation. During and after treatment, the main outcome measures include fasting blood glucose and 2-hour postprandial blood glucose.

Discussion: This research attempts to verify the clinical efficacy and possible mechanism of HJD in the treatment of prediabetes, and prove the consistency of HJD Formula Granules with HJD Elixation. This study also aims to provide a treatment that is both effective and safe for prediabetic patients.

Trial registration: ClinicalTrials.gov Identifier: ChiCTR2200060813, Registered 12 June 2022.

Keywords: Huoxue Jiangtang formula; Prediabetes; Randomized controlled trial; Traditional Chinese medicine.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Blood Glucose
  • Diabetes Mellitus* / drug therapy
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Lipids
  • Prediabetic State* / drug therapy
  • Prospective Studies
  • Randomized Controlled Trials as Topic

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Lipids